BACKGROUND: Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers.DESIGN AND METHODS: To evaluate International Prognostic Index (IPI) score before and after rituximab introduction and to validate the absolute lymphocyte count (ALC)/revised International Prognostic Index (R-IPI) model, we carried out a retrospective analysis on a total of 831 patients with DLBCL.RESULTS: Our results show that IPI lost its discriminating power with the introduction of rituximab. The analysis of our second set allowed us to validate the ALC/R-IPI model. The R-IPI and ALC/R-IPI could still be used for designing clinical trials, but both have difficulty recognizing a high percentage of poor prognosis patients, though it remains an important goal of a good prognostic model considering the modest impact of salvage treatments on survival.CONCLUSIONS: A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers are trying to hit a continuously moving target.

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story / Bari, Alessia; Marcheselli, Luigi; Sacchi, Stefano; Marcheselli, Raffaella; Pozzi, Samantha; Ferri, Paola; Balleari, E; Musto, P; Neri, S; Aloe Spiriti, Ma; Cox, M. C.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 21(7):(2009), pp. 1486-1491. [10.1093/annonc/mdp531]

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

BARI, Alessia;MARCHESELLI, Luigi;SACCHI, Stefano;MARCHESELLI, Raffaella;POZZI, Samantha;FERRI, Paola;
2009

Abstract

BACKGROUND: Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers.DESIGN AND METHODS: To evaluate International Prognostic Index (IPI) score before and after rituximab introduction and to validate the absolute lymphocyte count (ALC)/revised International Prognostic Index (R-IPI) model, we carried out a retrospective analysis on a total of 831 patients with DLBCL.RESULTS: Our results show that IPI lost its discriminating power with the introduction of rituximab. The analysis of our second set allowed us to validate the ALC/R-IPI model. The R-IPI and ALC/R-IPI could still be used for designing clinical trials, but both have difficulty recognizing a high percentage of poor prognosis patients, though it remains an important goal of a good prognostic model considering the modest impact of salvage treatments on survival.CONCLUSIONS: A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers are trying to hit a continuously moving target.
2009
21(7)
1486
1491
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story / Bari, Alessia; Marcheselli, Luigi; Sacchi, Stefano; Marcheselli, Raffaella; Pozzi, Samantha; Ferri, Paola; Balleari, E; Musto, P; Neri, S; Aloe Spiriti, Ma; Cox, M. C.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 21(7):(2009), pp. 1486-1491. [10.1093/annonc/mdp531]
Bari, Alessia; Marcheselli, Luigi; Sacchi, Stefano; Marcheselli, Raffaella; Pozzi, Samantha; Ferri, Paola; Balleari, E; Musto, P; Neri, S; Aloe Spiriti, Ma; Cox, M. C.
File in questo prodotto:
File Dimensione Formato  
Prognostic models for diffuse large B-cell lymphoma in the rituximab era.pdf

Accesso riservato

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 219.09 kB
Formato Adobe PDF
219.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/742299
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 77
social impact